HANCOCK JAFFE LABORATORIES news, videos and press releases
For more news please use our advanced search feature.
HANCOCK JAFFE LABORATORIES - More news...
HANCOCK JAFFE LABORATORIES - More news...
- enVVeno Medical to Present at Cowen's 43rd Annual Health Care Conference
- enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer
- Positive 3-Year VenoValve(R) First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular Issues
- enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study
- enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate Update
- enVVeno Medical Announces New U.S. VenoValve(R) Patent
- enVVeno Medical Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
- One-Year VenoValve(R) Data Published in Peer-Reviewed Journal, Vascular and Endovascular Surgery
- Positive Long-Term VenoValve(R) First-in-Human Data Presented at 34th Annual Meeting of the American Venous Forum
- enVVeno Medical Announces ISO 13485 Certification
- enVVeno Medical to Present at the Virtual Investor 2022 Top Picks Conference
- Hancock Jaffe Announces One Year Follow-up Data on Tenth VenoValve Patient
- Hancock Jaffe Announces Reverse Stock Split
- Hancock Jaffe's VenoValve(R) Results Featured in Journal of Vascular Surgery Venous and Lymphatic Disorders
- Hancock Jaffe Announces Date for VenoValve Pre-IDE Meeting with FDA
- Hancock Jaffe Reports Successful Completion of First CoreoGraft Heart Bypass Surgery
- Hancock Jaffe Submits VenoValve Pre-IDE Filing to FDA
- Hancock Jaffe to Begin CoreoGraft First-in-Human Study
- Hancock Jaffe Engages Syntactx for VenoValve U.S. Pivotal Trial
- Hancock Jaffe Laboratories, Inc. Announces Pricing of $5.1 Million Registered Direct Offering Priced at the Market
- Hancock Jaffe Announces Positive Nasdaq Listing Determination
- Hancock Jaffe Enrolls Initial Patients for First-in-Human CoreoGraft Study
- Hancock Jaffe Announces One Year Follow-up Data on Two Additional VenoValve Patients
- Hancock Jaffe Regains Compliance with Nasdaq Stockholder's Equity Rule
- Hancock Jaffe Receives Permission to Proceed with First-in-Human CoreoGraft Study
- Hancock Jaffe Laboratories Announces Closings of $6.2 Million Offerings Including Full Exercise of Over-Allotment Option
- Hancock Jaffe Laboratories Announces Pricing of $5.6 Million Offering
- Hancock Jaffe Announces Registered Direct Offering Priced At Market
- Hancock Jaffe Announces Intention to Merge with Catheter Precision
